|
Wed, 08/17/2022 - 01:25 |
US FDA accepts new drug application for GSKs momelotinib for the treatment of myelofibrosis |
GlaxoSmithKline |
|
Mon, 05/30/2022 - 02:40 |
Hundreds of new drug targets to combat tuberculosis |
RockefellerUniv... |
|
Mon, 11/23/2020 - 18:01 |
FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention |
FDA |
|
Fri, 03/20/2020 - 12:12 |
Artificial Intelligence May Help Predict Responses to Systemic Therapies in Patients With Non-small Cell Lung Cancer |
American Associ... |
|
Wed, 11/13/2019 - 16:56 |
Fresenius Kabi Announces Availability of Fosaprepitant for Injection 150 mg per vial |
Fresenius Kabi |
|
Sun, 09/29/2019 - 05:34 |
Genentech to Present Results of First Prospective Trial Using Blood-Based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib) |
Genentech |
|
Wed, 04/03/2019 - 02:39 |
News / VIZIMPRO (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer |
Pfizer |
|
Sun, 03/31/2019 - 02:20 |
Lupin receives U.S. FDA approval for Fosaprepitant for Injection |
Lupin |
|
Fri, 12/28/2018 - 07:47 |
Lupin receives tentative U.S. FDA approval for Fosaprepitant for Injection |
Lupin |
|
Thu, 06/14/2018 - 03:01 |
MERCURY PE is the first prospective, randomized trial to evaluate emergency department discharge in U.S. patients with low-risk PE |
Johnson and Johnson |
|
Sun, 06/03/2018 - 21:58 |
Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations |
Pfizer |
|
Wed, 05/16/2018 - 15:22 |
Follow-Up Phase III Data Showed Genentechs Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death |
Genentech |
|
Mon, 12/11/2017 - 05:42 |
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD) |
Johnson and Johnson |
|
Sun, 08/27/2017 - 01:19 |
XARELTO (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study |
Johnson and Johnson |
|
Mon, 08/21/2017 - 03:47 |
New XARELTO (rivaroxaban) Data at ESC Congress 2017Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study |
Johnson and Johnson |
|
Wed, 05/17/2017 - 18:47 |
Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting |
Pfizer |
|
Tue, 02/21/2017 - 00:16 |
Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer |
Rocheusa |
|
Sun, 01/01/2017 - 07:58 |
Other efficacy outcomes were evaluated in the study. Researchers found 1.9 percent of the XARELTO |
Johnson and Johnson |
|
Fri, 12/16/2016 - 13:37 |
CHMP recommends EU conditional approval of Roches Alecensa (alectinib) for people with previously treated ALK-positive NSCLC |
Rocheusa |
|
Tue, 11/01/2016 - 15:47 |
Two antibiotics fight bacteria differently than thought |
UICUniv |
|
Sat, 10/08/2016 - 23:31 |
Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016 |
Boehringer-Ingelheim |
|
Thu, 04/07/2016 - 08:34 |
Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung |
Boehringer-Ingelheim |
|
Mon, 12/21/2015 - 08:40 |
Powder for Oral Suspension 31.8%” |
Chugai |
|
Mon, 12/07/2015 - 18:30 |
Real-World Data Confirms Safety and Efficacy Profile of XARELTO ® , With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis |
Johnson and Johnson |
|
Fri, 07/24/2015 - 14:03 |
FDA APPROVES KYPROLIS® (CARFILZOMIB) FOR COMBINATION USE IN THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA |
MMRF |
